Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$115.45 USD

115.45
135,153

-6.63 (-5.43%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong

Shire (SHPG) reports better-than-expected first-quarter earnings and records strong growth in immunology franchise and newly launched products.

    Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark

    Sanofi (SNY) beat earnings but missed sales estimates in the first quarter of 2018 owing to exchange rate effects and struggling diabetes and cardiovascular unit.

      Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales

      Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.

        AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains

        AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

          Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up

          Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.

            BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat

            BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.

              Catalyst Enrolls First Patient in Phase III Firdapse Study

              Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis.

                Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer

                The FDA accepts Bristol-Myers Squibb's (BMY) supplemental Biologics License Application and grants priority review for the label expansion of Opdivo to treat patients with small cell lung cancer.

                  Calithera's Kidney Cancer Candidate Gets Fast Track Status

                  Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.

                    Bayer to Divest 3.6% Stake to Singapore Company Temasek

                    Bayer (BAYRY) will divest its 3.6% stake to Singapore's state investment company Temasek for total gross proceeds of ???3 billion.

                      Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline

                      The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.

                        Alnylam (ALNY) Reports Positive Data for RNAi Candidate

                        Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.

                          Alkermes Rallies as FDA Accepts NDA for Depression Drug

                          Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.

                            Merck's Keytruda Betters Survival in Lung Cancer Combo Study

                            Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.

                              Intercept Reports Phase III Sub-Study Liver Biopsy Data

                              Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis.

                                Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why

                                Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.

                                  Verastem (VSTM) in Focus: Stock Moves 8% Higher

                                  Shares of Verastem (VSTM) rose nearly 8% yesterday.

                                    FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy

                                    Bellicum (BLCM) agrees to make amendments to the protocols relating to clinical studies evaluating its T Cell Therapy, BPX-501.

                                      Zacks.com featured highlights include: Ligand, ArcelorMittal, 58.com, Ameresco and Mammoth Energy

                                      Zacks.com featured highlights include: Ligand, ArcelorMittal, 58.com, Ameresco and Mammoth Energy

                                        Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up

                                        Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity.

                                          Karyopharm's Myeloma Candidate Gets Fast Track Designation

                                          The FDA grants a fast track status to Karyopharm's (KPTI) selinexor for treatment of multiple myeloma. Selinexor is also evaluated in several mid- and later-phase studies on multiple cancer indications.

                                            FDA Prolongs Review Date for AbbVie Endometriosis Candidate

                                            The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.

                                              5 Best Profitable Stocks Offering Amazing Returns

                                              Net income ratio gives us the exact profitability level of a company and reflects the percentage of net income to total sales revenues.

                                                FDA Restricts Sale of Bayer's Essure Birth Control Device

                                                FDA puts restriction on the sale of Bayer's (BAYRY) implanted birth control device Essure.

                                                  Ionis (IONS) Clinches Licensing Agreement with AstraZeneca

                                                  Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.